Keyword: Copaxone

Teva's restructuring and cost-cutting initiatives are clearly working, but worries about generic competition to MS blockbuster Copaxone are putting pressure on Teva to continue to innovate.

A recently released FDA document shows that Pfizer's troubled fill-finish plant in Kansas was cited for continuing to repeat mistakes already cited by the FDA.

Novartis’ copycat arm, Sandoz, needed a win. And it got a key one Tuesday with the approval of generic 40-mg Copaxone.

Teva just went through a horrible year, today reporting a $17.5 billion operating loss in 2017, but execs said things will get worse before they get better.

Pfizer reported earnings today, including good news for Sandoz and partner Momenta.

Teva Pharmaceuticals, which has already paid $520 million in the U.S. for having bribed foreign doctors, has now settled with authorities in Israel.

Mylan’s long-acting Copaxone copy won FDA approval just three months ago, but it’s already gobbled up a sizable chunk of Teva’s market share.

For evidence that a pricing scandal can translate into real lost sales for a pharmaceutical company, look no further than Mylan's third-quarter results.

On a day that Teva chairman Sol Barer described as “the beginning of the next chapter for our company,” all analysts got was more of the same.

The patent pillars that have supported Teva’s defense of blockbuster Copaxone continue to fall with Mylan winning another legal battle In the U.K.